NEW OPPORTUNITIES IN TREATMENT OF JUVENILE ANKYLOSING SPONDYLOARTHRITIS

Development of effective and safe methods of treatment of juvenile ankylosing spondyloarthritis is one of topical problems of modern rheumatology. At the same time, the number of antirheumatic drugs used for the treatment of this disease is limited. It is necessary to widen a range of immunosuppressive medications for inclusion of genetically engineered biological agents. The objective of performed open-labeled trial was effectiveness and safety of monoclonal antibodies to tumor necrotizing factor (TNF) _ — infliximab. The study included 107 patients with juvenile ankylosing spondyloarthritis. 58 children were treated with infliximab, and 49 — with sulfasalazine. Duration of treatment was 54 weeks. In the end of a study 42% of patients treated with infliximab had status of inactive disease, and only 2% of patients in sulfasalazine group had the same status.Key words: children, juvenile ankylosing spondyloarthritis, infliximab, sulfasalazine, treatment.(Voprosy sovremennoi pediatrii — Current Pediatrics. 2010;9(2):23-31

EFFECTIVENESS OF INFLIXIMAB IN PATIENTS WITH JUVENILE ANKYLOSING SPONDYLARTHRITIS

The objective of open-labeled study was estimation of effectiveness and safety of infliximab — monoclonal antibodies to tumor necrosis factor (TNF) - in treatment of 48 patients with juvenile ankylosing spondylarthritis. Duration of observation was 6 weeks — 1,5 years. Anticytokine treatment was administrated on the ground of therapy with immunosuppressive agents in 96% of patients. Infliximab was administrated in median dose 7,4 ± 3,7 mg/kg of body weight by standard scheme (0–2–6 — week and further every 8 weeks) intravenously. Results of a trial showed that infliximab has evident anti-inflammatory effect. Treatment with infliximab provided development of remission of articular syndrome, decreasing and normalization of laboratory indices of activity of disease, the rate of disability, and increasing of quality of life in 84% of patients. Effect of this medication was registered after first infusion and continued during all period of follow up. Adverse effects included transfusion reactions: fever, head ache, nausea/vomiting in 10% of patients, allergic arthritis — in 2% of patients. Thus, treatment of infliximab is pathogenetically grounded, effective and safe in patients with juvenile ankylosing spondylarthritis.Key words: children, juvenile ankylosing spondylarthritis, infliximab, treatment.(Voprosy sovremennoi pediatrii — Current Pediatrics. 2009;8(2):20-26

Structure of Neuroglobin from Cold-Water Sponge Halisarca dujardinii

© 2020, Pleiades Publishing, Inc. Abstract: The iron-containing protein neuroglobin (Ngb) involved in the transport of oxygen is generally considered the precursor of all animal globins. In this report, we studied the structure of Ngb of the cold-water sponge Halisarca dujardinii. In sponges, the oldest multicellular organisms, the Ngb gene contains three introns. In contrast to human Ngb, its promoter contains a TATA-box, rather than CG-rich motifs. In sponges, Ngb consists of 169 amino acids showing rather low similarity with its mammalian orthologues. It lacks Glu and Arg residues in positions required for prevention of hypoxia-related apoptosis. Nevertheless, Ngb contains both proximal and distal conserved heme-biding histidines. The primary structure of H. dujardinii neuroglobin predicted by sequencing was confirmed by mass-spectrometry analysis of recombinant Ngb expressed in E. coli. The high level of Ngb expression in sponge tissues suggests its possible involvement in the gas metabolism and presumably in other key metabolic processes in H. dujardinii

Structure of Neuroglobin from Cold-Water Sponge Halisarca dujardinii

The iron-containing protein neuroglobin (Ngb) involved in the transport of oxygen is generally considered the precursor of all animal globins. In this report, we studied the structure of Ngb of the cold-water sponge Halisarca dujardinii. In sponges, the oldest multicellular organisms, the Ngb gene contains three introns. In contrast to human Ngb, its promoter contains a TATA-box, rather than CG-rich motifs. In sponges, Ngb consists of 169 amino acids showing rather low similarity with its mammalian orthologues. It lacks Glu and Arg residues in positions required for prevention of hypoxia-related apoptosis. Nevertheless, Ngb contains both proximal and distal conserved heme-biding histidines. The primary structure of H. dujardinii neuroglobin predicted by sequencing was confirmed by mass-spectrometry analysis of recombinant Ngb expressed in E. coli. The high level of Ngb expression in sponge tissues suggests its possible involvement in the gas metabolism and presumably in other key metabolic processes in H. dujardinii

CHILDREN'S ARTERIAL HYPERTENSION: DRUG CHOICE. THE RESULTS OF THE PHARMACOEPIDEMIOLOGICAL STUDY RIFAGD

The multicentered pharmacoepidemiological study «Rifagd» (prevalence and pharmacotherapy of arterial hypertension in children) in 13 cities of Russia was conducted with the purpose of analyzing of pediatricians' approach to the treatment of children's arterial hypertension, including drug choice. This allowed to estimate their experience, knowledge, as well as to direct the way to improvements of quality in medical treatment of patients with arterial hypertension. The majority of pediatricians (83,1%) encounter difficulties in hypertension treatment in connection with guidelines absence (37,3%), medical practice absence (30,4%) and «absence of indications for the application of antihypertensive drugs in pediatrics» (31,9%). for arterial hypertension treatment pediatricians use AgE-inhibitors, diuretics and beta blockers.Key words: rifagd, arterial hypertension, pharmacoepidemiology, questioning of pediatricians, ace inhibitors, diuretics, beta blockers

CHILDREN'S ARTERIAL HYPERTENSION: DRUG CHOICE. THE RESULTS OF THE PHARMACOEPIDEMIOLOGICAL STUDY RIFAGD

The multicentered pharmacoepidemiological study «Rifagd» (prevalence and pharmacotherapy of arterial hypertension in children) in 13 cities of Russia was conducted with the purpose of analyzing of pediatricians' approach to the treatment of children's arterial hypertension, including drug choice. This allowed to estimate their experience, knowledge, as well as to direct the way to improvements of quality in medical treatment of patients with arterial hypertension. The majority of pediatricians (83,1%) encounter difficulties in hypertension treatment in connection with guidelines absence (37,3%), medical practice absence (30,4%) and «absence of indications for the application of antihypertensive drugs in pediatrics» (31,9%). for arterial hypertension treatment pediatricians use AgE-inhibitors, diuretics and beta blockers.Key words: rifagd, arterial hypertension, pharmacoepidemiology, questioning of pediatricians, ace inhibitors, diuretics, beta blockers

HYPERPIESIS OF CHILDREN AND TEENAGERS: REAL PROBLEM FOR A PEDIATRICIAN

The authors have conducted multicentric epidemiological research in 13 cities of russia to examine approaches of pediatricians to diagnostics and treatment hyperpiesis in childhood, which allowed the researchers to estimate their experience and knowledge. It has turned out that most pediatricians can not apply the knowledge in hyperpiesis diagnostics due to the absence of the agebdependent cuffs to measure hyperpiesis, as well as the skills to assess the hyperpiesis measurement findings along with centile tables use. Quality improvement of hyperpiesis diagnostics in childhood is possible by means of implementation of educational programs for the pediatricians on diagnostics and treatment of children, suffering from hyperpiesis.Key words: child's hyperpiesis, epidemiology, diagnostics, children